Abstract
The European Medicines Agency (EMA) advises that all medicines containing soya-derived excipients should be labelled as contraindicated in peanut-allergic individuals. This is despite evidence of very little cross-reactivity between soya and peanut allergies. It is highly unlikely that patients with peanut allergy are at risk of a cross-reactive soya oil-based allergic reaction to soya protein in isotretinoin. This cross-sectional study has demonstrated the absence of IgE-sensitization to isotretinoin in peanut-allergic children and adolescents. Isotretinoin does not need to be avoided by peanut-allergic patients and we would encourage the EMA to alter their advice regarding soybean oil-containing medications to reflect this.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
